Skip to main content

Table 2 General characteristics and levels of SphK-related sphingolipids at follow-up in the control and incident T2DM groups

From: Identification of circulating sphingosine kinase-related metabolites for prediction of type 2 diabetes

Characteristic

Control

(n = 100)

Incident T2DM

(n = 100)

P value

Age, years

66.8 (60.3–74.0)

66.3 (60.3–72.2)

0.999

Body mass index, kg/m2

24.9 ± 3.1

25.7 ± 3.4

0.080

Waist circumference, cm

83.1 ± 9.2

85.5 ± 9.8

0.083

Total Cholesterol (mmol/L)

5.06 (4.41–5.64)

5.13 (4.37–5.80)

0.500

LDL (mmol/L)

2.94 ± 0.80

2.87 ± 0.89

0.523

HDL (mmol/L)

1.42 (1.12–1.69)

1.33 (1.16–1.62)

0.602

Triglycerides (mmol/L)

1.37 (1.06–1.78)

1.72 (1.27–2.30)

0.026

Fasting plasm glucose (mmol/L)

5.30 (5.10–5.60)

6.10 (5.45–7.25)

 < 0.001

OGTT 2 h-plasm glucose (mmol/L)

6.10 (5.45–6.90)

12.1 (11.3–13.8)

 < 0.001

Insulin (μU/mL)

6.90 (5.00–9.80)

10.8 (6.50–15.7)

 < 0.001

HOMA-IR

1.62 (1.11–2.33)

2.81 (1.69–4.81)

 < 0.001

Uric acid (μmol/L)

309.0 (256.0–379.5)

321.0 (265.5–377.5)

0.774

Systolic blood pressure (mmHg)

138.0 ± 20.2

142.0 ± 18.4

0.149

Diastolic blood pressure (mmHg)

77.1 ± 11.5

78.5 ± 8.6

0.335

Sphingolipids (nmol/L)

   

 Sph

12.6 (7.58–19.1)

14.3 (6.8–20.7)

0.110

 S1P

740.5 (575.7–987.1)

781.1 (550.3–1072)

0.225

 S1P/Sph

60.3 (43.8–94.1)

59.9 (39.6–93.8)

0.497

 dhSph

2.88 (2.09–3.87)

3.03 (2.15–3.74)

0.570

 dhS1P

132.2 (107.7–174.2)

166.6 (103.6–203.3)

0.021

 dhS1P/dhSph

45.0 (35.6–63.9)

54.8 (44.0–66.3)

0.024

  1. Data are presented as mean ± SD, except for skewed variables, which are presented as the median with the interquartile range given in parentheses